PRECISION NEUROLOGY & NEURO-ONCOLOGY
FOR BRAIN HEALTH
BRAIN-SPECIFIC TARGET AND THERAPEUTICS
Our brain is in total control of our body. Yet, there are barely any disease-modifying treatments for brain diseases.
AIMEDBIO utilizes big data analysis and its proprietary precision medicine platform to select brain-specific targets for which brain therapeutics show the most efficacy.
BRAIN-SPECIFIC IMMUNE MODULATOR
Along with population ageing, patients with neurodegenerative diseases are rapidly increasing. Destroyed balance in the brain's immune system often causes these neurodegenerative diseases.
Since the brain's immune system is like no other organs', AIMEDBIO's long dedication to brain research works as a great advantage in developing brain-specific immune modulators.
BRAIN-SPECIFIC THERAPEUTICS WITH ENHANCED DELIVERY
The brain with its impregnable defense system, the blood-brain barrier, has always been a key obstacle in brain therapeutics development.
AIMEDBIO's BBB-crossing technologies combined with its pipelines serve as a great tool in developing efficient brain therapeutics.
AIMEDBIO is a spin-off company from Samsung Medical Center that has been established in August 2018 with the sole purpose of pursuing after attainable treatment solutions to patients with refractory brain disease, including cancer, in hopes of providing better quality of life. Our primary objective is based on data-driven personalized treatment to address current medical unmet needs in the field of brain disease through international collaborations that we have solidified through years of close partnership.
I have been continuing my journey against brain disease since 1989 as a neurosurgeon with one specific goal in mind, providing optimal solution to individual patient. Our team at AIMEDBIO has never stopped innovation for creating scientific breakthrough, technological advances and new discoveries. AIMEDBIO has been continuing its heritage of leadership in the field of brain & tumor. We have an excellent research team with profound achievements, own R&D pipelines with outstanding drug development platform and are building strong global networks with key opinion leaders in the field. We believe that our culture and challenges will be the fundamental elements of our continued success.
Do-Hyun Nam, M.D, Ph.D.
Founder and Chief Technology Officer